; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) address unmet and underserved medical needs in women's health. Our product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:

  • JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
  • JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
  • JNP-0301, a natural progesterone IVR for the prevention of preterm birth.

Our R&D programs are supported by cash flow generated by Crinone® (progest  More >>

Stock Quote

JNP (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Down 0.05 (0.95%)
Data as of 01/20/17 3:39 p.m. ET
Minimum 20 minute delayRefresh quote
JNP Investor Presentation: January 2017
Recent NewsMore >>
01/06/17Juniper Pharmaceuticals Unveils Strategic and Product Development Objectives for 2017Printer Friendly Version
01/05/17Juniper Pharmaceuticals Announces Poster Presentation at Society for Maternal-Fetal Medicine 2017 Annual MeetingPrinter Friendly Version
12/20/16Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial OfficerPrinter Friendly Version
11/15/16Juniper Pharmaceuticals Monetizes U.S. Crinone Royalty Stream with AllerganPrinter Friendly Version